| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702807 | Urologic Oncology: Seminars and Original Investigations | 2016 | 8 Pages |
Abstract
In patients with NMIBC, markers of systemic inflammation response are associated with disease recurrence and progression. The inclusion of such markers in prognostic models does enhance their accuracy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Aurélie M.D., Shahrokh F. M.D., Malte M.D., Michael M.D., Evanguelos M.D., Christian M.D., Ilaria M.D., Romain M.D., Morgan M.D., Alberto M.D., Pierre I. M.D., Tobias M.D.,